Binzen, Germany
Binzen, Germany

Time filter

Source Type

News Article | May 15, 2017
Site: www.prnewswire.com

•         The market is segmented on the basis of product, application, end user, and geography. •         The integrated systems segment is expected to account for the largest share of the continuous manufacturing market in 2017. •         The integrated systems enable end-to-end manufacturing to convert raw materials into final products. •         Product launch was the dominant strategy adopted by key industry participants to increase their market share and cater to unmet needs The global continuous manufacturing market is expected to reach USD 650.4 million by 2022 from USD 348.5 million in 2017, at a CAGR of 13.3%. The market is segmented on the basis of product, application, end user, and geography. The product segment includes integrated systems, semi-continuous systems, and controls. The integrated systems segment is expected to account for the largest share of the continuous manufacturing market in 2017. The integrated systems enable end-to-end manufacturing to convert raw materials into final products. In addition, these systems save substantial cost and time by integrating various pharmaceutical processes in a single system. By application, the end product manufacturing segment is estimated to account for the largest share of the market, in 2017. FDA approval for certain drugs manufactured by the continuous process is the primary factor driving the growth of this segment. On the basis of end user, the full-scale manufacturing companies are expected to hold the highest share of the market, in 2017. The large share of this segment can primarily be attributed to the increasing adoption of continuous technologies by pharmaceutical manufacturing companies and CMOs to address the challenges related to product quality, drug supply, and operational costs. Product launch was the dominant strategy adopted by key industry participants to increase their market share and cater to unmet needs. Major players include GEA Group AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bosch Packaging Technology (Germany), Coperion GmbH (Germany), and Glatt GmbH (Germany). Other players include KORSCH AG (Germany), Munson Machinery Company, Inc. (U.S.), L.B. Bohle Maschinen + Verfahren Gmbh (Germany), Gebrder Ldige Maschinenbau GmbH (Germany), Baker Perkins Ltd. (U.K.), Scott Equipment Company (U.S.), and Sturtevant, Inc. (U.S.). This report studies the continuous manufacturing market based on product, application, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends, prospects, and contributions to the total market. The report forecasts revenue of the market segments with respect to four main regions. The report will enable both established firms and new entrants to gauge the pulse of the market and to help them make important strategic growth decisions. The report provides insights on the following: Product Development/Innovation: Product portfolios of the top players in the continuous manufacturing market. Detailed insights on upcoming technologies, R&D activities, and product launches on the upcoming continuous manufacturing market Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of the leading players in the continuous manufacturing market Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various continuous manufacturing systems across geographies Market Diversification: Exhaustive information about new products, recent developments, and investments in the continuous manufacturing market ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/continuous-manufacturing-market-is-expected-to-reach-usd-6504-million-by-2022-300457907.html


Browse 162 tables and 52 figures, 13 Company profiles spread across 181 pages available at The global continuous manufacturing market is expected to reach USD 650.4 million by 2022 from USD 348.5 million in 2017, at a CAGR of 13.3%. The market is segmented on the basis of product, application, end user, and geography. The product segment includes integrated systems, semi-continuous systems, and controls. The integrated systems segment is expected to account for the largest share of the continuous manufacturing market in 2017. The integrated systems enable end-to-end manufacturing to convert raw materials into final products. In addition, these systems save substantial cost and time by integrating various pharmaceutical processes in a single system. By application, the end product manufacturing segment is estimated to account for the largest share of the market, in 2017. FDA approval for certain drugs manufactured by the continuous process is the primary factor driving the growth of this segment. On the basis of end user, the full-scale manufacturing companies are expected to hold the highest share of the market, in 2017. The large share of this segment can primarily be attributed to the increasing adoption of continuous technologies by pharmaceutical manufacturing companies and CMOs to address the challenges related to product quality, drug supply, and operational costs. The geographic segments in this report include North America, Europe, Asia-Pacific, and RoW. Of these, the North American segment is expected to account for the largest share of the market in 2017. This large share can primarily be attributed to the support from regulatory bodies, initiation by leading pharmaceutical companies, and the need for pharmaceutical manufacturers to reduce rising operational costs and eliminate issues related to the inconsistent quality of pharmaceutical products produced through batch manufacturing. Product launch was the dominant strategy adopted by key industry participants to increase their market share and cater to unmet needs. Major players include GEA Group AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bosch Packaging Technology (Germany), Coperion GmbH (Germany), and Glatt GmbH (Germany). Other players include KORSCH AG (Germany), Munson Machinery Company, Inc. (U.S.), L.B. Bohle Maschinen + Verfahren Gmbh (Germany), Gebruder Lodige Maschinenbau GmbH (Germany), Baker Perkins Ltd. (U.K.), Scott Equipment Company (U.S.), and Sturtevant, Inc. (U.S.). Order a copy of Continuous Manufacturing Market By Product (Integrated system, Semi-continuous (Granulator, Coater, Blender), Control), Application (API, End Product (Solid Dosage)), End User (R&D Department (CRO), Pharmaceutical Companies, CMO) - Global Forecast to 2022 Research Report at Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021. Explore more reports on Pharmaceuticals market Research at ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.


Browse 162 tables and 52 figures, 13 Company profiles spread across 181 pages available at The global continuous manufacturing market is expected to reach USD 650.4 million by 2022 from USD 348.5 million in 2017, at a CAGR of 13.3%. The market is segmented on the basis of product, application, end user, and geography. The product segment includes integrated systems, semi-continuous systems, and controls. The integrated systems segment is expected to account for the largest share of the continuous manufacturing market in 2017. The integrated systems enable end-to-end manufacturing to convert raw materials into final products. In addition, these systems save substantial cost and time by integrating various pharmaceutical processes in a single system. By application, the end product manufacturing segment is estimated to account for the largest share of the market, in 2017. FDA approval for certain drugs manufactured by the continuous process is the primary factor driving the growth of this segment. On the basis of end user, the full-scale manufacturing companies are expected to hold the highest share of the market, in 2017. The large share of this segment can primarily be attributed to the increasing adoption of continuous technologies by pharmaceutical manufacturing companies and CMOs to address the challenges related to product quality, drug supply, and operational costs. The geographic segments in this report include North America, Europe, Asia-Pacific, and RoW. Of these, the North American segment is expected to account for the largest share of the market in 2017. This large share can primarily be attributed to the support from regulatory bodies, initiation by leading pharmaceutical companies, and the need for pharmaceutical manufacturers to reduce rising operational costs and eliminate issues related to the inconsistent quality of pharmaceutical products produced through batch manufacturing. Product launch was the dominant strategy adopted by key industry participants to increase their market share and cater to unmet needs. Major players include GEA Group AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Bosch Packaging Technology (Germany), Coperion GmbH (Germany), and Glatt GmbH (Germany). Other players include KORSCH AG (Germany), Munson Machinery Company, Inc. (U.S.), L.B. Bohle Maschinen + Verfahren Gmbh (Germany), Gebruder Lodige Maschinenbau GmbH (Germany), Baker Perkins Ltd. (U.K.), Scott Equipment Company (U.S.), and Sturtevant, Inc. (U.S.). Order a copy of Continuous Manufacturing Market By Product (Integrated system, Semi-continuous (Granulator, Coater, Blender), Control), Application (API, End Product (Solid Dosage)), End User (R&D Department (CRO), Pharmaceutical Companies, CMO) - Global Forecast to 2022 Research Report at Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021. Explore more reports on Pharmaceuticals market Research at ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.


The invention relates to a catalytically active porous element and to a method of manufacturing same. The element is formed with at least 40% by mass cobalt and at least one further chemical element and/or at least one chemical compound which form a matrix into which particles of pure cobalt, of a cobalt alloy or of an intermetallic phase formed with cobalt are embedded. In this respect, the at least one chemical element and/or the at least one chemical compound have a lower sintering temperature and/or melting temperature than cobalt, the respective cobalt alloy or the intermetallic phase. Solely for this purpose or in addition thereto, cobalt can be partially soluble therein and/or can form a eutectic and/or a peritectic together with cobalt.


Patent
Glatt Ag | Date: 2013-03-26

Taste-masked Ibuprofen granules and a process for preparation thereof, as well as an oral dosage form including such taste-masked Ibuprofen granules and the use of said granules in an oral dosage form.


In the method in accordance with the invention of manufacturing an open-cell body from a metal or ceramic material, a procedure is followed such that individual parts of an open pore plastic in a size which corresponds to the size of the bodies to be manufactured while taking account of the shrinkage on a sintering or an open pore plastic element having predetermined break points which take account of the size and geometrical design of bodies to be manufactured while considering the shrinkage in the sintering are/is infiltrated and coated with a suspension in which, in addition to a liquid, at least one powdery material is contained with which the bodies are manufactured. Organic components are expelled after a first heat treatment. Subsequently, a sintering is carried out in which open-cell bodies are obtained, wherein the parts of porous plastic provided with the suspension are separated before the first heat treatment and/or sintering or wherein, after the sintering, the open-cell element which is obtained from the plastic element from the material with which the bodies are formed is cut by forces acting at the desired break points and thereby bodies can be obtained which are present in separated form.


A pharmaceutical composition is described which includes diclofenac as an active ingredient. The pharmaceutical composition further includes a (meth)acrylic polymer which has a specific solubility and/or a particular functional group in one polymer component.


The invention relates to a method for producing particles with a length-width ratio of less than about 1.4 from a pharmaceutical substance, which method includes the following stages, that is: (a) provision of a melt of the pharmaceutical substance; (b) production of droplets of the melt by spraying into a processing chamber; (c) repeated guiding of solid particles past sprayed droplets in the processing chamber with the aid of a process gas jet which is guided in a defined way and whose temperature is fixed, depending on the solidification point of the melt, so that at least some of the droplets come into contact with particles and solidify thereon; (d) removal of particles from the processing chamber as a function of the particle size. The invention further relates to particles of pharmaceutical substances and the use thereof.


The invention relates to a method for producing particles with a length-width ratio of less than about 1.4 from a pharmaceutical substance, which method includes the following stages, that is: (a) provision of a melt of the pharmaceutical substance; (b) production of droplets of the melt by spraying into a processing chamber; (c) repeated guiding of solid particles past sprayed droplets in the processing chamber with the aid of a process gas jet which is guided in a defined way and whose temperature is fixed, depending on the solidification point of the melt, so that at least some of the droplets come into contact with particles and solidify thereon; (d) removal of particles from the processing chamber as a function of the particle size. The invention further relates to particles of pharmaceutical substances and the use thereof.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH-2011.4.2-1 | Award Amount: 5.52M | Year: 2011

The aim of TAIN is to develop a neonatal formulation of hydrocortisone, a drug included in the EMA priority list that needs specific evaluation in the age range 0 2 years (neonates & infants). Hydrocortisone is an essential glucocorticoid hormone used as replacement therapy for the treatment of congenital and acquired adrenal insufficiency as well playing an important therapeutic role in oncology in infants, specifically brain tumours and leukaemias. TAIN involves European leaders in neonatology, paediatric pharmacology, methodology and SMEs that will establish links with ethical bodies and regulatory authorities. The programme will perform in silico experiments and evaluate formulations for neonates. The phase 3 clinical trial comparing the neonatal hydrocortisone versus current (unlicensed) therapy will be optimized using age-appropriate state-of-the-art methods adapted to neonates (including in silico experiments and pharmacokinetics) to validate the components of a Paediatric Investigation Plan. It will be performed by neonatologists trained in paediatric pharmacology and clinical research in line with guidelines on Good Clinical Practice. All the ethical issues will be considered, including pain and distress, blood sampling (number and volume) and informed consent. Parent information sheets and consent form will be submitted to patient and parents associations for approval. TAIN will include short term safety studies and Phase 3 clinical studies in neonates and infants. Results will be reported in order to allow a PUMA application to be submitted and to improve neonatal and infant care. Therefore, TAIN will validate the appropriate use of hydrocortisone in neonates and infants which will be of direct benefit to children, their families and health professionals. TAIN will strengthen paediatric drug evaluation across Europe and build up a network of units with experience in clinical research that will be used for additional drug evaluation in neonates.

Loading Glatt GmbH collaborators
Loading Glatt GmbH collaborators